Trial Profile
An Exploratory, Double-Blind, Randomized, Placebo Controlled Study Evaluating Topical Recombinant Human Vascular Endothelial Growth Factor (Telbermin) for Induction of Healing of Chronic, Diabetic Foot Ulcers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Telbermin (Primary)
- Indications Diabetic foot ulcer
- Focus Adverse reactions
- Sponsors Genentech
- 21 Oct 2014 New trial record